ALX Oncology - UBS Global Biopharma Conference - ALX ONCOLOGY HOLDINGS INC
Explicit Guidance:
- ALX2004 (EGFR ADC) Enrollment: Expecting 35+ patients total in the Phase 1 study, with 15+ patients enrolled in dose-expansion cohorts at therapeutic doses; enrollment focus narrowed to Non-Small Cell Lung Cancer (NSCLC) and Head and Neck Squamous Cell Carcinoma (HNSCC).
- ALX2004 Data Readout: Phase 1 top-line safety and efficacy data expected in December (specifically prior to the company's holiday party, estimated late November/early December).
- EvorPRECEP (CD47 ADC) Enrollment: Phase 2 study (ASPEN-9) in HER2+ metastatic breast cancer targeted for 120 patients.
- EvorPRECEP Data Readout: Top-line results for response rates and CD47 cut-point optimization expected in the second half of 2027.
- Liquidity: Cash runway extended through mid-2028 following a $150 million raise in January 2024.
Business-Segment Outlook:
- ALX2004 (EGFR ADC):
- Target Validation: Anticipated to demonstrate significantly reduced on-target toxicity (rash) compared to competitors like cetuximab, targeting <20% total rash incidence (vs. ~70-80% historically) to prevent dose discontinuation.
- Efficacy Targets: Aims for double-digit response rates in 4th-line HNSCC and NSCLC as a benchmark; >30% response rate considered "transformational" and the primary goal.
- Pipeline Expansion: Plans to advance into 2nd-line settings immediately following Phase 1 data:
- Head and Neck: Will evaluate EGFR-naive patients and those who have progressed on prior EGFR therapies (e.g., pembrolizumab/pembrolizumab-like agents) utilizing a unique epitope (metuzumab-based) distinct from current bispecifics.
- Lung: Focusing on EGFR wild-type (squamous) populations where current Topo-ADCs (e.g., sacituzumab govitecan) and antibody combinations show limited efficacy or unmet needs.
- EvorPRECEP (CD47 ADC):
- Study Design: Phase 2 ASPEN-9 designed as an "internal control" to validate the CD47 overexpression threshold (defined as >4-5%) in HER2+ patients.
- Differentiation Strategy: Expects to show superior efficacy in CD47-high patients vs. the historical 15% response rate seen in retreatment scenarios (post-HER2 failure), aiming to double real-world standards of care.
- Biomarker Optimization: Goal is to finalize the CD47 positivity cut-point prior to Phase 3 initiation.
- ALX2004 (EGFR ADC):
Market and Competitive Outlook:
- ALX2004 Competitive Position:
- Differentiates via a unique epitope (metuzumab-derived) compared to cetuximab/pertuzumab, potentially overcoming resistance mechanisms (epitope mutations) seen in patients progressing on existing therapies.
- Addresses a high unmet need in squamous NSCLC and 2nd-line HNSCC, areas where current Topo-ADCs (e.g., Ado-trastuzumab deruxtecan) have struggled or are not approved.
- Anticipates strong demand for alternatives post-first-line pembrolizumab or bispecifics in head and neck.
- EvorPRECEP Market Opportunity:
- Targets a multi-billion dollar indication (HER2+ metastatic breast cancer).
- Positioning as the "first and only option" specifically for CD47-high patients, leveraging the synergy of CD47 blockade + HER2 ADC activity (ADCC).
- Current standard of care in 2nd-line+ HER2+ breast cancer shows abysmal outcomes (14-15% ORR); a doubling of response rates would be clinically significant.
- ALX2004 Competitive Position:
Macro / Industry Outlook:
- Therapeutic Landscape Shifts: Acknowledges the potential approval of bispecifics (e.g., Pemra-1/Peto) moving into first-line head and neck, creating a subsequent need for effective post-bispecific therapies in 2nd line.
- Standard of Care Evolution: Highlights the lack of effective options in 4th-line HNSCC/NSCLC (current options limited to docetaxel with <15% response) and the shifting dynamics in breast cancer post-HER2 failure.
- Biomarker Trends: Emphasizes the industry shift toward precision medicine requiring rigorous biomarker validation (fresh tissue vs. archival) to identify responders (HER2 and CD47 status).
Strategic Initiatives:
- Enrollment Prioritization: Shifted ALX2004 enrollment strategy to prioritize NSCLC and HNSCC cohorts over gastric/esophageal to maximize statistical power for registrational readiness in high-probability tumors.
- Biomarker Protocol Refinement: Implementing strict requirements for fresh tissue biopsies and ctDNA testing in ASPEN-9 to ensure accurate HER2 and CD47 stratification, acknowledging that ~30% of archival HER2+ cases may be discordant.
- Capacity Planning: Maintaining a lean operational structure with sufficient capital to reach all stated milestones (Phase 1 data, Phase 2 enrollment completion) without additional financing needs through mid-2028.
Risks and Headwinds to Outlook:
- Toxicity Profile: Risk that the novel EGFR epitope may still induce on-target skin toxicity (rash) if the mechanism of action mimics cetuximab's wild-type expression, potentially leading to dose reductions or discontinuations.
- Biomarker Discordance: Risk that archival tissue testing may misclassify patients as HER2+ when fresh tissue is negative, or that CD47 expression thresholds may not perfectly correlate with clinical response.
- Enrollment Constraints: Dependency on late-line (4th line) patient availability for ALX2004 expansion; potential delays if patient recruitment at top US centers is slower than projected.
- Regulatory Uncertainty: The "transformative" efficacy targets (>30%) must be met in the 2nd-line setting to justify regulatory progression; failure to demonstrate superiority in 4th-line data could delay 2nd-line trials.
Management Tone on the Future:
- High Confidence: Expresses strong enthusiasm regarding the "inflection points" for both programs, describing the ALX2004 data as "encouraging" and the EvorPRECEP strategy as "compelling."
- Aggressive Pacing: Demonstrates urgency to move ALX2004 into 2nd-line trials quickly, citing the "big opportunities" in HNSCC and lung before standard of care is fully locked in by new first-line agents.
- Financial Discipline: Reassures investors with a clear, funded runway (through mid-2028) and a strategic focus on data generation over premature commercialization.
- Hedging: Acknowledges the historical difficulty of EGFR ADCs (Big Pharma failures) but counters with specific mechanistic advantages (metuzumab epitope) and the necessity of keeping patients on drug to achieve efficacy.
Miscellaneous:
- Data Timing: Explicitly states data will be released "very soon" (December) but avoids specific dates around the Christmas holiday.
- Study Design Specifics: ALX2004 Phase 1 aims for a Dose-Limiting Toxicity (DLT) related to payload, targeting 4 mg/kg as the therapeutic ceiling.
- Geographic Focus: ASPEN-9 enrollment primarily in top US academic centers (e.g., MD Anderson, Moffitt).
- Company
- ALX ONCOLOGY HOLDINGS INC
- Keywords
- ALX ONCOLOGY HOLDINGS INC